Skip to content
10-Q

Quarterly Report

AMYLIN PHARMACEUTICALS INC

0000881464-12-000006

← back to feed
Filed
May 7, 2012 12:00 AM ET
Period of report

On SEC.gov

Financials in this filing

Metric Period Value
Cash And Equivalents Q1 2012 · Jan 1, 2013 $99.86M
Cash And Equivalents Q1 2012 · Mar 31, 2012 $73.4M
Cash And Equivalents Q1 2012 · Dec 31, 2011 $99.86M
Cash And Equivalents Q1 2012 · Mar 31, 2011 $248.15M
Cash And Equivalents Q1 2012 · Dec 31, 2010 $164.52M
Shares Outstanding Q1 2012 · Apr 26, 2012 162.85M sh
Capex Q1 2012 · Mar 31, 2012 $10.35M
Capex Q1 2012 · Mar 31, 2011 $10.01M
Operating Cash Flow Q1 2012 · Mar 31, 2012 −$93.36M
Operating Cash Flow Q1 2012 · Mar 31, 2011 $23.1M
Short Term Debt Q1 2012 · Mar 31, 2012 $68.3M
Short Term Debt Q1 2012 · Dec 31, 2011 $63.55M
Stockholders Equity Q1 2012 · Mar 31, 2012 $8.29M
Stockholders Equity Q1 2012 · Dec 31, 2011 −$138.75M
Current Liabilities Q1 2012 · Mar 31, 2012 $290.21M
Current Liabilities Q1 2012 · Dec 31, 2011 $296.02M
Current Assets Q1 2012 · Mar 31, 2012 $561.25M
Current Assets Q1 2012 · Dec 31, 2011 $421.19M
Total Assets Q1 2012 · Mar 31, 2012 $2.01B
Total Assets Q1 2012 · Dec 31, 2011 $1.87B
Sga Expense Q1 2012 · Mar 31, 2012 $110.35M
Sga Expense Q1 2012 · Mar 31, 2011 $64.63M
Rd Expense Q1 2012 · Mar 31, 2012 $51.24M
Rd Expense Q1 2012 · Mar 31, 2011 $41.92M
Net Income Q1 2012 · Mar 31, 2012 −$99.04M
Net Income Q1 2012 · Mar 31, 2011 −$37.32M
Operating Income Q1 2012 · Mar 31, 2012 −$54.33M
Operating Income Q1 2012 · Mar 31, 2011 −$29.08M
Cost Of Revenue Q1 2012 · Mar 31, 2012 $34.56M
Cost Of Revenue Q1 2012 · Mar 31, 2011 $12.54M
Revenue Q1 2012 · Mar 31, 2012 $153.69M
Revenue Q1 2012 · Mar 31, 2011 $152.71M